HopeStage
Back to all studies
CompletedNCT01314001

Nicotine Metabolism and Response to Smoking-Cessation Treatments

About this titleRead the official source — NCT01314001
Medication studyAges 18–65United States + CanadaAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Buffalo and 3 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2010
Recruitment status
Completed
Enrollment listed in the registry
1,246
Sponsor
University of Pennsylvania
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT01314001
Official title
Show the full official title

Pharmacogenetics of Nicotine Addiction Treatment (PNAT)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Buffalo, United States · Philadelphia, United States · Houston, United States

1 more locations
  • Toronto, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Pennsylvania, a university.

Did this study involve medication?

Yes. The study involved medication, including Varenicline, Placebo and Transdermal Nicotine.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies